创新药多点突破,华东医药、礼来、诺华多维绽放

医药经济报
08 Apr

全球仅3款,华东医药三靶点抗体融合蛋白获批临床4月7日,华东医药发布公告,其控股子公司道尔生物申报的注射用 DR30206 临床试验申请获得批准,联合标准化疗,拟用于晚期或转移性消化道肿瘤患者。据悉,DR30206 是由道尔生物自主研发并拥有全球知识产权的 1 类治疗用生物制品,为一款靶向 PD-L1、VEGF 和 TGF-β 的抗体融合蛋白。此前,DR30206 于 2023 年 4 月首次在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10